Erik was appointed CFO of Targovax in April 2017, and led the NOK 200 million private placement in June 2017. He already plays an integral role in the Company’s strategic operations and business development activities. By transitioning Erik into the CBO role, Targovax will be better able to leverage his strong scientific background in cancer research.
“We are delighted to announce the appointment of Torbjørn Furuseth as our new CFO. He brings a wealth of financial and industry experience, which will be instrumental in progressing Targovax’s investor relations and strategy,” said Øystein Soug, CEO of Targovax. “At the same time, Erik Digman Wiklund moves from being CFO to become Chief Business Officer, with responsibility for all our business development activities. Over the past 18 months, Erik has become a highly valued member of the Targovax team, and his deep insights in both the scientific and business aspects of biotech equips him to be a very effective CBO. Erik and Torbjørn have previously worked together both at McKinsey & Co and Aker Biomarine, I therefore look forward to harnessing their strong working relationship and driving Targovax forward as we continue to advance our immuno-oncology pipeline through clinical development.”